Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors in the central nervous system, conolidine modulates alternate molecular targets. A Science Advances study discovered that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://thefairlist.com/story10997524/conolidin-to-replace-traditional-painkillers-options